SCHEMBL26316620

SCHEMBL26316620

Cc1ccc(/C=C/c2nc(C(=O)Nc3ccc(CCCCO)cc3)co2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.40
RAB9A P51151 5/20 0.40
TP53 P04637 4/20 0.40
ALDH1A1 P00352 3/20 0.40
GLA P06280 1/20 0.40
HTT P42858 1/20 0.40
ERBB2 P04626 1/20 0.40
GAA P10253 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
CYP3A4 P08684 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CCR5 P51681 1/20 0.36
SPHK1 Q9NYA1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22398039 0.87 ERBB2 (0.47) RAB9AALDH1A1ERBB2HDAC1HDAC8
SCHEMBL22398036 0.87 ERBB2 (0.47) RAB9AALDH1A1ERBB2HDAC1HDAC8
SCHEMBL26316624 0.84 ERBB2 (0.50) NPC1RAB9ATP53ALDH1A1GLA
SCHEMBL24111975 0.81 SMO (0.40) NPC1RAB9AALDH1A1HTTHDAC1
SCHEMBL26316613 0.80 ERBB2 (0.64) ALDH1A1ERBB2GAAMEN1KMT2A
SCHEMBL26316627 0.79 KMT2A (0.40) NPC1RAB9AALDH1A1HTTERBB2
SCHEMBL28469073 0.77 ERBB2 (0.43) RAB9AALDH1A1ERBB2HDAC1HDAC8
SCHEMBL26316563 0.73 ERBB2 (0.54) NPC1RAB9AALDH1A1ERBB2SMN1; SMN2
SCHEMBL22397938 0.73 ERBB2 (0.64) RAB9AALDH1A1ERBB2MEN1KMT2A
SCHEMBL28477867 0.73 ERBB2 (0.64) RAB9AALDH1A1ERBB2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 NPC1 3392/4885RAB9A 2806/4885TP53 63/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 NPC1 3909/4885RAB9A 2786/4885TP53 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.